Short-term monotherapy with Liraglutide for weight management: A case study
Background: Liraglutide 3 mg was approved by the FDA as an antiobesity drug. A recent study reported that short-term treatment with Liraglutide (20.0 ± 6.4 days) reduces body weight. Case Presentation: A 35-year-old male not having any medical illness was presented for medical weight-loss management...
Main Author: | Feras Almarshad |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Journal of Family Medicine and Primary Care |
Subjects: | |
Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2019;volume=8;issue=5;spage=1804;epage=1806;aulast=Almarshad |
Similar Items
-
Liraglutide for weight management: a critical review of the evidence
by: A. Mehta, et al.
Published: (2017-03-01) -
Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
by: Inoue Kana, et al.
Published: (2011-12-01) -
Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01) -
Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial
by: Aditi R. Saxena, et al.
Published: (2021-06-01) -
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)